Levodopa/Carbidopa/Entacapon Stada

Levodopa, carbidopa, and entacapone, the active ingredients in Levodopa/Carbidopa/Entacapon Stada, are a Levodopa/Carbidopa/Entacapone combination presented as an oral tablet for oral use. The formulation combines a dopamine precursor with peripheral decarboxylase inhibition and COMT inhibition to enhance central dopaminergic activity. They are employed to manage motor symptoms of Parkinson's disease in adult patients.\n\nGNH India supplies Levodopa/Carbidopa/Entacapon Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements to ensure product integrity across global markets.

Levodopa/Carbidopa/Entacapone is indicated for the treatment of Parkinson's disease, where it helps to improve motor function, reduce OFF episodes, and allow more stable symptom control across disease stages.\n- Early-stage Parkinson's disease: improves tremor, rigidity, and bradykinesia.\n- Advanced Parkinson's disease: reduces OFF periods and motor fluctuations.\n- Fluctuating response to levodopa: enhances and prolongs dopaminergic effect.\n- Adjunct therapy with levodopa: enables lower levodopa dosing while maintaining efficacy.\n- Early morning akinesia: provides smoother onset of motor activity.

Levodopa/Carbidopa/Entacapone may be associated with a range of adverse reactions.\n\nCommon Side Effects:\n- Nausea\n- Dizziness or light‑headedness\n- Orthostatic hypotension\n- Insomnia\n\nSerious or Rare Side Effects:\n- Severe dyskinesia\n- Neuroleptic malignant syndrome\n- Life‑threatening hypotension\n- Anaphylactic reactions

When prescribing Levodopa/Carbidopa/Entacapone, clinicians should consider several precautionary measures to ensure safe use.\n- Renal impairment: monitor renal function and adjust therapy as needed.\n- Hepatic impairment: use with caution and observe liver enzymes.\n- Cardiovascular disease: watch for orthostatic hypotension and arrhythmias.\n- Psychiatric history: monitor for hallucinations, confusion, or mood changes.\n- Concomitant MAO‑B inhibitors: avoid co‑administration due to risk of hypertensive crisis.\n- Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Levodopa/Carbidopa/Entacapone can interact with several medicines, affecting its efficacy or safety.\n\nMajor Interactions (Avoid):\n- Non‑selective MAO inhibitors: